DOI: https://doi.org/10.29363/nanoge.amamed.2022.008
Publication date: 22nd April 2022
Iron oxide nanoparticles (IONP) are the eternal promise to change the molecular imaging field. This promise has not become a reality due to the unfavourable imaging features of traditional iron oxide nanoparticles for many diseases, i.e. the negative contrast in magnetic resonance imaging (MRI). Our group has focused on making IONP really useful for molecular imaging. For that, we developed extremely small 68Ga core-doped iron oxide nano-radiomaterials. These nanotracers provide simultaneous positive contrast in MRI and PET signal allowing for an unambiguous diagnosis of several diseases in animal models. Recently, these nano-radiomaterials have been used for the diagnosis of cancer,[1,2] inflammatory diseases,[3] atherosclerosis[4,5] and thrombosis.[6]
Here, I’ll show our latest results in the use of these nano-radiomaterials, particularly for the diagnosis of vascular diseases and how the combined use of these nanotracers with bioorthogonal chemistry may change the way molecular imaging is carried out.
This work was supported by the Spanish Ministry of Science (grant nos. SAF2016-79593-P, RED2018-102469-T, and PID2019-104059RB-I00). This research work was performed in the framework of the Nanomedicine CSIC HUB (ref 202180E048)